Literature DB >> 19341605

Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007.

H De Carvalho Gomes1, M Muscat, D L Monnet, J Giesecke, P L Lopalco.   

Abstract

The first pneumococcal vaccine targeting the youngest age groups, a seven-valent conjugate vaccine (PCV7), was licensed in Europe in 2001. Since then several European countries have introduced PCV7 in their childhood vaccination schedules.Still, information on vaccination schemes, vaccine uptake and impact of vaccine introduction is scarce in Europe. The following article summarises the characteristics of national pneumococcal vaccination programmes for children in 32 European countries and provides an estimate of vaccine use based on sales data for 22 countries between 2001 and 2007. There were wide variations in the recommended PCV7 vaccination schemes and in PCV7 use.High vaccine uptake was not always related to the presence of a national vaccination programme.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19341605

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  18 in total

1.  Genome-wide identification of Streptococcus pneumoniae genes essential for bacterial replication during experimental meningitis.

Authors:  T E Molzen; P Burghout; H J Bootsma; C T Brandt; Christa E van der Gaast-de Jongh; M J Eleveld; M M Verbeek; N Frimodt-Møller; C Østergaard; P W M Hermans
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

Review 2.  Paediatric pneumococcal disease in Central Europe.

Authors:  R Prymula; R Chlibek; I Ivaskeviciene; A Mangarov; Zs Mészner; P Perenovska; D Richter; N Salman; P Simurka; E Tamm; G Tešović; I Urbancikova; V Usonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-11       Impact factor: 3.267

3.  Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.

Authors:  Filippo Ansaldi; Daniela de Florentiis; Paola Canepa; Antonella Ceravolo; Emanuela Rappazzo; Rocco Iudici; Mariano Martini; Gerardo Botti; Andrea Orsi; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 4.  Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Authors:  Chantal W B Boonacker; Pieter H Broos; Elisabeth A M Sanders; Anne G M Schilder; Maroeska M Rovers
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

5.  Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.

Authors:  L Schuerman; J Wysocki; J C Tejedor; M Knuf; K-H Kim; J Poolman
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

6.  Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.

Authors:  Alessia Melegaro; Yoon Hong Choi; Robert George; W John Edmunds; Elizabeth Miller; Nigel J Gay
Journal:  BMC Infect Dis       Date:  2010-04-08       Impact factor: 3.090

7.  Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.

Authors:  Gerwin D Rodenburg; Sabine C de Greeff; Angelique G C S Jansen; Hester E de Melker; Leo M Schouls; Eelko Hak; Lodewijk Spanjaard; Elisabeth A M Sanders; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

8.  The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy.

Authors:  Enrica Riva; Filippo Salvini; Maria Laura Garlaschi; Giovanni Radaelli; Marcello Giovannini
Journal:  BMC Infect Dis       Date:  2012-05-03       Impact factor: 3.090

9.  Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens.

Authors:  Teresa Jackowska; Justyna Pluta
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

10.  Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.

Authors:  Zitta B Harboe; Palle Valentiner-Branth; Helene Ingels; Jeppe N Rasmussen; Peter H S Andersen; Catherine C Bjerre; David Goldblatt; Lindsey Ashton; Mitch Haston; Helle B Konradsen; Lotte Lambertsen
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.